Machine signal
Active cluster sell — 6 distinct insiders, $3.6M, window ends Aug 12, 2026.
Figures computed from official regulatory filings — .
Analysttarget 60.57 USD (+51%) · consensus 4.75/5 · 7 buy · 1 hold · 0 sell
Ownershipinsiders 1.19% · institutions 111.06% · short 13.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Vericel Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
57 buys262 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| MCLAUGHLIN KEVIN F | Exercise | $91.4K | Unusual size | SEC |
| MCLAUGHLIN KEVIN F | Sell | $311.7K | SEC |
| MCLAUGHLIN KEVIN F | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Halpin Michael | Sell | $468.4K | SEC |
| Halpin Michael | Exercise | $166.6K | Unusual size | SEC |
| Halpin Michael | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIEGAL JONATHAN | Sell | $24.5K | SEC |
| SIEGAL JONATHAN | Sell | $122.3K | SEC |
| SIEGAL JONATHAN | Exercise | $52.4K | SEC |
| SIEGAL JONATHAN | Sell | $73.4K | SEC |
| SIEGAL JONATHAN | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIEGAL JONATHAN | Exercise | $14.9K | SEC |
| SIEGAL JONATHAN | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIEGAL JONATHAN | Exercise | $74.6K | SEC |
| SIEGAL JONATHAN | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Flynn Sean C. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIEGAL JONATHAN | Sell | $10.4K | SEC |
| Flynn Sean C. | Sell | $684.6K | SEC |
| Mara Joseph Anthony Jr | Sell | $223.8K | SEC |
| Hopper Jonathan Mark | Exercise | $149.1K | SEC |
| Flynn Sean C. | Exercise | $243.8K | Unusual size | SEC |
| Hopper Jonathan Mark | Exercise | $149.1K | SEC |
| SIEGAL JONATHAN | Exercise | $74.6K | SEC |
| Hopper Jonathan Mark | Sell | $225K | SEC |
| Hopper Jonathan Mark | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |